Zobrazeno 1 - 10
of 95
pro vyhledávání: '"K. Wollschlaeger"'
Autor:
L. Palmere, K. Wollschlaeger
Publikováno v:
American Journal of Obstetrics and Gynecology. 226:S1337-S1338
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2048f4cb74a3d7d1c50b6b4e432d3b79
https://doi.org/10.1016/j.ajog.2021.12.117
https://doi.org/10.1016/j.ajog.2021.12.117
Autor:
K. Wollschlaeger, Timothy J. Perren, Jacobus Pfisterer, Alexandra Leary, Gabe S. Sonke, Gilles Freyer, O. Tome, Olivier Colomban, L. Van Wagensveld, R. Kruitwagen, M. Van Der Aa, Michel Tod, M-C. Kaminsky-Forrett, Benoit You, Adrian Cook, A. du Bois, Frédéric Selle, Alain Lortholary, Florence Joly
Publikováno v:
Annals of Oncology. 31:S616
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::429fc78b01166c08d5549910ca5370ca
https://doi.org/10.1016/j.annonc.2020.08.954
https://doi.org/10.1016/j.annonc.2020.08.954
Publikováno v:
Geburtshilfe und Frauenheilkunde.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dad77cf508c40a88dd15d46dd0576c73
https://doi.org/10.1055/s-0038-1671269
https://doi.org/10.1055/s-0038-1671269
Autor:
Jens Huober, Barbara Schmalfeldt, Pauline Wimberger, Werner Meier, Behnaz Aminossadati, Peter Hillemanns, Winfried Siffert, Jan Dominik Kuhlmann, Alexander Burges, Jalid Sehouli, Hagen S. Bachmann, K. Wollschlaeger, Andreas du Bois, Rainer Kimmig
Publikováno v:
British Journal of Clinical Pharmacology. 80:1139-1148
Aim Despite promising preclinical findings regarding clinical utility of farnesyltransferase inhibitors (FTI), such as lonafarnib, success of clinical trials is limited. A multicentre AGO-OVAR-15 phase II trial reported an unfavourable effect of lona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d962ffad3148f2a700109db3c2468af6
https://doi.org/10.1111/bcp.12688
https://doi.org/10.1111/bcp.12688
Autor:
K. Wollschlaeger, Pauline Wimberger, Linn Woelber, Peter Hillemanns, N. Ewald-Riegler, Alexander Burges, S Kommoss, Annette Hasenburg, Tanja Fehm, Friedrich Kommoss, Barbara Richter, Werner Meier, Steffen Hauptmann, Eik Vettorazzi, Felix Hilpert, Karsten Muenstedt, Klaus Baumann, HG Strauss, B Schmalfeldt, M-D Keyver-Paik, Ulrich Canzler, Fabian Trillsch, W. Schroeder, Martin Hellriegel, N de Gregorio, A. du Bois, Christina Fotopoulou, Alexander Reuss, Lars Hanker, Dirk Forner, Sven Mahner, Jacobus Pfisterer
Publikováno v:
British Journal of Cancer
Background: Incomplete surgical staging is a negative prognostic factor for patients with borderline ovarian tumours (BOT). However, little is known about the prognostic impact of each individual staging procedure. Methods: Clinical parameters of 950
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ddc3e57542d7f2556cce0527d5a8e13
http://europepmc.org/articles/PMC4333495
http://europepmc.org/articles/PMC4333495
Publikováno v:
Zeitschrift für Geburtshilfe und Neonatologie.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9aeb74c8f069ebae339c5813eb560242
https://doi.org/10.1055/s-0037-1607781
https://doi.org/10.1055/s-0037-1607781
Autor:
Mignon-Denise Keyver-Paik, Ulrich Canzler, Sven Mahner, Klaus Baumann, A. du Bois, Christina Fotopoulou, Barbara Richter, Tanja Fehm, Pauline Wimberger, Jacobus Pfisterer, Annette Hasenburg, K. Wollschlaeger, Peter Hillemanns, Friedrich Kommoss, Felix Hilpert, N. Ewald-Riegler, B Schmalfeldt, Lars Hanker, Eik Vettorazzi, W. Schroeder, Fabian Trillsch, Alexander Burges, Alexander Reuss, Dirk Forner, N de Gregorio, Steffen Hauptmann, Linn Woelber, HG Strauss, Werner Meier, Karsten Muenstedt, Martin Hellriegel
Publikováno v:
Annals of Oncology. 25:1320-1327
BACKGROUND Approximately one-third of all borderline ovarian tumours (BOT) are diagnosed in patients with child-bearing potential. Detailed information regarding their specific characteristics and prognostic factors is limited. METHODS Clinical param
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12c07bcaeef826ff4b7a96338be70b70
https://doi.org/10.1093/annonc/mdu119
https://doi.org/10.1093/annonc/mdu119
Autor:
Alexander Burges, W. Schröder, Annette Hasenburg, B Schmalfeldt, Klaus Baumann, Mignon-Denise Keyver-Paik, Christina Fotopoulou, Friedrich Kommoss, Hans-Georg Strauss, Andreas du Bois, Ulrich Canzler, Nikolaus de Gregorio, Barbara Richter, Stefan Kommoss, Tanja Fehm, K. Wollschlaeger, Martin Hellriegel, Steffen Hauptmann, Werner Meier, K. Münstedt, Felix Hilpert, Jacobus Pfisterer, Lars Hanker, Alexander Reuss, Peter Hillemanns, N. Ewald-Riegler, Dirk Forner, Sven Mahner, Pauline Wimberger
Publikováno v:
European Journal of Cancer. 49:1905-1914
Background Borderline ovarian tumours (BOTs) are recognised as a unique entity of ovarian tumours that do not exert infiltrative destructive growth or stromal invasion. Prognosis of BOT is much better compared to the more common invasive epithelial o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30b28a23fd6fad4c96f01881dd8c0adf
https://doi.org/10.1016/j.ejca.2013.01.035
https://doi.org/10.1016/j.ejca.2013.01.035
Autor:
Christina Fotopoulou, Rong Jiang, Philipp Harter, K. Wollschlaeger, H. Oksefjell, Yan Xing, Wen Juan Tian, Jalid Sehouli, Jonathan S. Berek, Ali Ayhan, Catherine Rabbitt, Jacobus Pfisterer, Elena-Ioana Braicu, Dennis S. Chi, Gennaro Cormio, A. du Bois, Claes G. Tropé, Rongyu Zang
Publikováno v:
British Journal of Cancer
Background: This study aims to identify prognostic factors and to develop a risk model predicting survival in patients undergoing secondary cytoreductive surgery (SCR) for recurrent epithelial ovarian cancer. Methods: Individual data of 1100 patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba3aa53657554acd3585584db37e90a2
https://doi.org/10.1038/bjc.2011.328
https://doi.org/10.1038/bjc.2011.328
Autor:
Felix Hilpert, A. du Bois, Rainer Kimmig, C. Jackisch, Antje Belau, Jacobus Pfisterer, Ulrich Canzler, S. Loibl, Jalid Sehouli, Alexander Reuss, Silke Reinartz, V. Heilmann, K. Wollschlaeger
Publikováno v:
Annals of Oncology. 17:1568-1577
Background: Abagovomab is a murine anti-idiotypic antibody against the antigen CA-125 which has been shown to elicit humoral and cellular immune responses against ovarian cancer (oc). Patients and methods: This phase I trial included 36 patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2834515b9efc240171be2ce80b9cda53
https://doi.org/10.1093/annonc/mdl357
https://doi.org/10.1093/annonc/mdl357